Henlius Biotech announces licensing deals

Shanghai Henlius Biotech (2696: HK) today revealed it has entered into a strategic collaboration with fellow Chinese drug developer GeneQuantum Healthcare, and with UK-based Envision Pharma. No financial terms of the deals were disclosed.

As agreed with GeneQuantum, Henlius will obtain the development and exclusive commercialization rights for the innovative HER2-targeted antibody-drug conjugate (ADC) GQ1005 in China and certain overseas markets. The drug candidate, currently in Phase III clinical development, is being evaluated for HER2-positive breast cancer.

Ping Cao, chief business development officer and senior vice president of Henlius, stated: "As a leader in breast cancer treatment, Henlius is dedicated to advancing treatment innovation and delivering clinical breakthroughs. Our core breast cancer therapies have now been approved in over 50 countries and regions worldwide. This collaboration will expand our end-to-end treatment paradigm across all breast cancer subtypes, further solidifying our leadership position. We look forward to bringing this innovative medicine to patients as soon as possible, igniting hope for more lives."